Atrial fibrillation (AF) is an independent risk factor for stroke. Anticoagulation therapy has a risk of intracerebral hemorrhage. The use of percutaneous left atrial appendage (LAA) closure devices is an alternative to anticoagulation therapy. Echocardiography has a leading role in LAA closure procedure in patient selection, during the procedure and during followup. A comprehensive echocardiography study is necessary preprocedural in order to identify all the lobes of the LAA, evaluate the size of the LAA ostium, look for thrombus or spontaneous echo contrast, and evaluate atrial anatomy, including atrial septal defect and patent foramen ovale. Echocardiography is used to identify potential cardiac sources of embolism, such as atrial septal aneurysm, mitral valve disease, and aortic debris. During the LAA occlusion procedure transeosophageal echocardiography provides guidance for the transeptal puncture and monitoring during the release of the closure device. Procedure-related complications can be evaluated and acceptable device release criteria such as proper position and seating of the occluder in the LAA, compression, and stability can be assessed. Postprocedural echocardiography is used for followup to assess the closure of the LAA ostium. This overview paper describes the emerging role of LAA occlusion procedure with transeosophageal echocardiography guidance as an alternative to anticoagulation therapy in patients with AF.
Keyphrases
- atrial fibrillation
- left atrial appendage
- left ventricular
- left atrial
- catheter ablation
- oral anticoagulants
- mitral valve
- pulmonary hypertension
- computed tomography
- heart failure
- minimally invasive
- direct oral anticoagulants
- hypertrophic cardiomyopathy
- percutaneous coronary intervention
- magnetic resonance
- coronary artery
- venous thromboembolism
- subarachnoid hemorrhage
- magnetic resonance imaging
- ultrasound guided
- brain injury
- risk factors
- contrast enhanced
- blood brain barrier
- pulmonary arterial hypertension